Partnership for clinics and distributors

4STIM supplies rehabilitation clinics and distributors with a complete translingual neurostimulation (TLNS) program: the device, the treatment methodology and staff training — delivered as a new clinical service line that starts with a 90-day pilot.

Who this is for

Rehabilitation centers and neurology clinics that treat patients after stroke and traumatic brain injury, children with cerebral palsy, and adults with multiple sclerosis, Parkinson's disease or balance disorders. Medical equipment distributors looking for a differentiated neurorehabilitation product with a clinical evidence base. Physicians and entrepreneurs opening a rehabilitation practice.

The problem we solve for a clinic

Most rehabilitation programs plateau: after the first months, patients with chronic neurological deficits stop improving, drop out, or move on to another provider. Clinics compete on the same set of methods and have few ways to offer something measurably different. Adding a new neuromodulation direction usually means expensive equipment, a long learning curve and no patient flow to justify it.

What you get

• A portable TLNS device that a patient uses during therapeutic exercises — 20-minute sessions, 2–3 times a day. After two weeks of supervised sessions in the clinic, the patient continues at home with remote follow-up, and the device stays with the patient.
• A treatment methodology with protocols by indication (cerebral palsy, stroke, TBI, multiple sclerosis, Parkinson's disease, vestibular and postural disorders), patient selection criteria, outcome scales and a documentation template.
• Training for your team — physicians, physiotherapists and nurses — delivered on site or online, with ongoing case supervision from our clinical staff.
• Patient-facing materials in English and Spanish: brochure, explainer video, FAQ, and access to our Telegram assistant for pre-screening.

Why TLNS from 4STIM

Translingual neurostimulation was developed at the Tactile Communication and Neurorehabilitation Laboratory (TCNL) of the University of Wisconsin–Madison. The scientific lead of our program, Yuri Danilov, is a senior scientist of TCNL and co-author of the key TLNS publications. We do not adapt someone else's product: we continue the same scientific school, extend it to new indications and run it every day in our own rehabilitation centers in Moscow and Tashkent.

• Broader indications than any other TLNS system on the market, including a pediatric program for children from two years of age.
• Evidence base: 36+ peer-reviewed publications, 500+ patients in clinical studies, 7,000+ patients in clinical practice. In a controlled study of 134 children with spastic cerebral palsy, the TLNS group improved gross motor function nearly three times faster than standard rehabilitation alone, and gains accumulated from cycle to cycle instead of returning to baseline. See Clinical Evidence.
• Regulatory status: the RehaLine TLNS device is registered in Russia, Mexico (COFEPRIS), Uzbekistan and New Zealand; registration is in progress in Brazil, Vietnam and the Philippines. The device is not FDA-cleared and is not offered in the United States.
• Cost of entry several times lower than comparable systems, with a device that remains with the patient — which opens a home-therapy revenue model for the clinic, not just in-clinic sessions.
• Safety record: no serious device-related adverse events in the published studies; the most common effect is mild tingling of the tongue.

How the pilot works

1. Introductory call (45 minutes). We walk through the technology, the evidence for your patient profile and the economics of the program in your setting.
2. Pilot design (2 weeks). Together we define the indication, the number of patients (typically 5–10), outcome measures and the training schedule. You receive the pilot agreement and the commercial terms.
3. 90-day clinical pilot. Devices are delivered, your team is trained, the first patients start under our supervision. We review outcomes with you every two weeks.
4. Scale-up. On the basis of pilot results you decide on the program format: in-clinic service, home-therapy program, or regional distribution.

What we ask from a partner

A licensed medical facility or distributor, at least one physician responsible for the program, and the readiness to collect outcome data with the scales we agree on. Everything else — protocols, training, materials, and the remote supervision of first cases — is on our side.

Next step

Write to info@4stim.com, message us on Telegram, or use the form below. Tell us your country, the type of facility and the patient groups you work with — we will send the partnership presentation and propose a time for the introductory call.